| Literature DB >> 29387151 |
Wenpeng You1, Maciej Henneberg1,2.
Abstract
Cancer incidence increase has multiple aetiologies. Mutant alleles accumulation in populations may be one of them due to strong heritability of many cancers. The opportunity for the operation of natural selection has decreased in the past ~150 years because of reduction in mortality and fertility. Mutation-selection balance may have been disturbed in this process and genes providing background for some cancers may have been accumulating in human gene pools. Worldwide, based on the WHO statistics for 173 countries the index of the opportunity for selection is strongly inversely correlated with cancer incidence in peoples aged 0-49 years and in people of all ages. This relationship remains significant when gross domestic product per capita (GDP), life expectancy of older people (e50), obesity, physical inactivity, smoking and urbanization are kept statistically constant for fifteen (15) of twenty-seven (27) individual cancers incidence rates. Twelve (12) cancers which are not correlated with relaxed natural selection after considering the six potential confounders are largely attributable to external causes like viruses and toxins. Ratios of the average cancer incidence rates of the 10 countries with lowest opportunities for selection to the average cancer incidence rates of the 10 countries with highest opportunities for selection are 2.3 (all cancers at all ages), 2.4 (all cancers in 0-49 years age group), 5.7 (average ratios of strongly genetically based cancers) and 2.1 (average ratios of cancers with less genetic background).Entities:
Keywords: biological state index; cancer heritability; life expectancy; mutations
Year: 2017 PMID: 29387151 PMCID: PMC5775494 DOI: 10.1111/eva.12523
Source DB: PubMed Journal: Evol Appl ISSN: 1752-4571 Impact factor: 5.183
Figure 2The relationship between I s and residual of all cancer incidence rate (+50, all ages) standardized on gross domestic product per capita (GDP)
Figure 1The relationship between I s and all cancer incidence rate (all ages)
Spearman rho and partial correlations between I s and all cancers incidence rates at all ages and 0‐49 years, and for 27 separate site cancers (Bold indicates significant coefficients)
| Independent variables (Cancer) | All countries | Incidence | Countries with “high‐quality” data | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonparametric | Partial | Nonparametric | Partial | ||||||||||||
| rho |
|
|
|
|
| Effect size | Increase | rho |
|
|
|
|
| Effect size | |
| All cancers (C00‐97, but C44), all ages | −0.738 | <.001 | 173 | − | <.001 | 98 | 0.113 | 2.326 | −0.650 | <.001 | 64 | − | .024 | 40 | 0.132 |
| All cancers (C00‐97, but C44), 0–49 | −0.719 | <.001 | 173 | − | <.001 | 99 | 0.168 | 2.386 | −0.607 | <.001 | 64 | − | .003 | 41 | 0.248 |
| Bladder (C67) | −0.709 | <.001 | 173 | − | .030 | 98 | 0.049 | 4.126 | −0.571 | <.001 | 64 | −.248 | .114 | 40 | 0.065 |
| Brain (C70‐72) | −0.738 | <.001 | 170 | − | .013 | 98 | 0.065 | 6.585 | −0.389 | <.001 | 64 | − | .008 | 40 | 0.196 |
| Breast (C50) | −0.737 | <.001 | 173 | − | .003 | 98 | 0.092 | 2.698 | −0.723 | <.001 | 64 | −.300 | .054 | 40 | 0.099 |
| Cervix uteri (C53) | 0.608 | <.001 | 173 | .071 | .485 | 98 | 0.005 | 0.206 | 0.407 | <.001 | 64 | −.040 | .803 | 40 | 0.002 |
| Colorectum (C18‐21) | −0.845 | <.001 | 173 | − | <.001 | 98 | 0.261 | 7.008 | −0.723 | <.001 | 64 | − | .004 | 40 | 0.231 |
| Corpus uteri (C54) | −0.674 | <.001 | 172 | − | <.001 | 98 | 0.128 | 3.837 | −0.528 | <.001 | 64 | − | .008 | 40 | 0.196 |
| Gallbladder (C23‐24) | −0.509 | <.001 | 158 | − | .024 | 98 | 0.054 | 5.230 | −0.096 | .452 | 63 | .106 | .502 | 40 | 0.011 |
| Hodgkin lymphoma (C81) | −0.666 | <.001 | 166 | − | .007 | 98 | 0.078 | 3.314 | −0.491 | <.001 | 64 | − | .024 | 40 | 0.137 |
| Kaposi sarcoma (C46) | 0.564 | <.001 | 120 | .325 | .004 | 76 | 0.118 | 0.061 | 0.286 | .052 | 47 | .275 | .128 | 30 | 0.082 |
| Kidney (C64‐66) | −0.850 | <.001 | 167 | − | <.001 | 98 | 0.308 | 10.023 | −0.562 | <.001 | 64 | − | .005 | 40 | 0.221 |
| Larynx (C32) | −0.448 | <.001 | 168 | −.144 | .154 | 98 | 0.021 | 2.248 | 0.005 | .966 | 64 | −.182 | .248 | 40 | 0.034 |
| Leukaemia (C91‐95) | −0.800 | <.001 | 171 | − | <.001 | 98 | 0.182 | 3.574 | −0.585 | <.001 | 64 | − | .022 | 40 | 0.141 |
| Lip and oral cavity (C00‐08) | −0.257 | <.001 | 173 | −.037 | .712 | 98 | 0.001 | 1.334 | −0.359 | .004 | 64 | − | .030 | 40 | 0.126 |
| Liver (C22) | 0.300 | <.001 | 173 | −.033 | .745 | 98 | 0.001 | 0.624 | 0.041 | .750 | 64 | .136 | .392 | 40 | 0.019 |
| Lung (C33‐34) | −0.782 | <.001 | 173 | − | .003 | 98 | 0.095 | 11.933 | −0.483 | <.001 | 64 | −.244 | .119 | 40 | 0.064 |
| Melanoma of skin (C43) | −0.482 | <.001 | 168 | −.155 | .124 | 98 | 0.025 | 10.286 | −0.613 | <.001 | 63 | −.283 | .069 | 40 | 0.087 |
| Multiple myeloma (C88, C90) | −0.663 | <.001 | 157 | − | .018 | 98 | 0.059 | 4.257 | −0.547 | <.001 | 64 | −.077 | .626 | 40 | 0.006 |
| Nasopharynx (C11) | 0.221 | <.001 | 154 | .114 | .257 | 98 | 0.013 | 0.767 | 0.334 | .008 | 63 | .144 | .364 | 40 | 0.021 |
| Non‐Hodgkin lymphoma (C82‐85, C96) | −0.524 | <.001 | 173 | .031 | .756 | 98 | 0.001 | 2.019 | −0.565 | <.001 | 64 | −.114 | .472 | 40 | 0.013 |
| Oesophagus (C15) | 0.009 | .907 | 172 | .132 | .189 | 98 | 0.018 | 0.529 | 0.008 | .951 | 64 | −.004 | .978 | 40 | 0.000 |
| Other pharynx (C09‐10, C12‐14) | −0.347 | <.001 | 168 | −.091 | .367 | 98 | 0.008 | 2.037 | −0.371 | .003 | 63 | −.263 | .093 | 40 | 0.074 |
| Ovary (C56) | −0.608 | <.001 | 173 | − | .002 | 98 | 0.106 | 1.997 | −0.449 | <.001 | 64 | − | .002 | 40 | 0.282 |
| Pancreas (C25) | −0.802 | <.001 | 170 | − | <.001 | 98 | 0.258 | 5.142 | −0.602 | <.001 | 64 | − | .009 | 40 | 0.186 |
| Prostate (C61) | −0.498 | <.001 | 173 | −.114 | .260 | 98 | 0.013 | 3.463 | −0.577 | <.001 | 64 | −.301 | .053 | 40 | 0.100 |
| Stomach (C16) | −0.412 | <.001 | 173 | − | .015 | 98 | 0.063 | 1.826 | 0.049 | .700 | 64 | −.281 | .072 | 40 | 0.086 |
| Testis (C62) | −0.777 | <.001 | 153 | − | <.001 | 98 | 0.110 | 14.579 | −0.681 | <.001 | 64 | − | .002 | 40 | 0.267 |
| Thyroid (C73) | −0.684 | <.001 | 170 | − | <.001 | 98 | 0.115 | 5.362 | −0.346 | .005 | 64 | −.113 | .477 | 40 | 0.013 |
| GDP PPP 2010 | −0.853 | <.001 | 168 | – | – | – | – | – | −0.760 | <.001 | 63 | – | – | – | – |
| Life expect ( | −0.822 | <.001 | 173 | – | – | – | – | – | −0.666 | <.001 | 64 | – | – | – | – |
| Obesity | −0.572 | <.001 | 173 | – | – | – | – | – | −0.003 | .984 | 64 | – | – | – | – |
| Physical inactivity | −0.315 | <.001 | 132 | – | – | – | – | – | −0.103 | .453 | 55 | – | – | – | – |
| Smoking, Daily any tobacco product 2011 | −0.551 | <.001 | 123 | – | – | – | – | – | −0.234 | .086 | 55 | – | – | – | – |
| Urbanization 2010 | −0.712 | <.001 | 169 | – | – | – | – | – | −0.455 | <.001 | 64 | – | – | – | – |
Life expectancy (e50) was not controlled as it is not relevant in people aged 0–49 years.
Partial correlations were calculated when GDP, life expectancy (e50), obesity, physical inactivity, smoking and urbanization were kept statistically constant.
Ratio of lowest 10 I s countries to highest I s 10 countries: Average strong genetic cancer incidence rate ratio: 5.718, Average less genetic cancer incidence rate ratio 2.143. “Strong genetic cancer” refers to those individual (site) cancers whose incidence rates were significantly and negatively correlated with I s in partial correlation. “Less genetic cancers” refers to those individual cancers whose incidence rates were not significantly or negatively correlated with I s.
Figure 3The relationship between relaxation of natural selection and incidence of selected cancers
Results of multiple linear regression analyses to identify predictors of cancer incidence
| Variable | All countries ( | Variable | Countries with “high‐quality” data ( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All ages | 0–49 years old | All ages | 0–49 years old | ||||||
| Beta | Sig. | Beta | Sig. | Beta | Sig. | Beta | Sig. | ||
| Enter | |||||||||
|
| −0.373 | 0.014 | −0.523 | 0.000 |
| −0.809 | 0.011 | −1.090 | <0.001 |
| GDP | 0.190 | 0.207 | 0.254 | 0.000 | GDP | −0.417 | 0.174 | −0.308 | 0.345 |
| Life expectancy | 0.126 | 0.241 | – | – | Life expectancy | 0.434 | 0.009 | – | − |
| Obesity | 0.100 | 0.211 | 0.040 | 0.608 | Obesity | 0.213 | 0.087 | −0.002 | 0.987 |
| Physical Inactivity | −0.071 | 0.339 | −0.057 | 0.436 | Physical inactivity | −0.232 | 0.092 | −0.192 | 0.189 |
| Smoking | 0.220 | 0.007 | 0.204 | 0.011 | Smoking | −0.016 | 0.911 | 0.015 | 0.920 |
| Urbanization | −0.059 | 0.499 | −0.164 | 0.056 | Urbanization | −0.131 | 0.547 | −0.224 | 0.336 |
Associations between I s and cancer incidence (all ages) in different country groupings
| Pearson's | Nonparametric | |||
|---|---|---|---|---|
| Pearson's | Significance | Spearman's rho | Significance | |
| WHO region | ||||
| AFRO, | −0.151 | 0.329 | −0.099 | 0.523 |
| AMRO, | −0.695 | <0.001 | −0.662 | <0.001 |
| EMRO, | −0.043 | 0.852 | 0.081 | 0.729 |
| EURO, | −0.800 | <0.001 | −0.738 | <0.001 |
| SEARO, | −0.034 | 0.920 | −0.191 | 0.574 |
| WPRO, | −0.590 | 0.008 | −0.599 | 0.007 |
| The World Bank income | ||||
| High, | −0.402 | 0.005 | −0.311 | 0.032 |
| Upper middle, | −0.647 | <0.001 | −0.577 | <0.001 |
| Low middle, | −0.425 | 0.003 | −0.418 | 0.003 |
| Low, | −0.166 | 0.381 | −0.104 | 0.586 |
| Other country groupings | ||||
| Arab World, | −0.152 | 0.512 | −0.086 | 0.710 |
| English, official language, | −0.692 | <0.001 | −0.625 | <0.001 |
| OECD, | −0.539 | <0.001 | −0.204 | 0.255 |
| APEC, | −0.616 | 0.005 | −0.730 | <0.001 |
| ACD, | −0.447 | 0.019 | −0.373 | 0.055 |
| SADC, | −0.243 | 0.403 | −0.169 | 0.563 |